Home › Von Hippel-Lindau Disease › Tennessee
Von Hippel-Lindau Disease clinical trials in Tennessee
3 studies for Von Hippel-Lindau Disease are looking for participants at sites in Tennessee.
Belzutifan/MK-6482 for the Treatment of Advanced Pheochromocytoma/Paraganglioma (PPGL), Pancreatic Neuroendocrine Tumor (pNET), Von Hippel-Lindau (VHL) Disease-Associated Tumors, Advanced Gastrointestinal Stromal Tumor (wt GIST), or Solid Tumors With HIF-2α Related Genetic Alterations (MK-6482-015)
- Vanderbilt University Medical Center ( Site 0107), Nashville
RecruitingPhase 2
Ages 12 and older · All sexes · Updated Sep 25, 2026 · NCT04924075Extension Study for Participants in Studies That Include Belzutifan (MK-6482-043/LITESPARK-043)
- SCRI Oncology Partners ( Site 7000), Nashville
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 23, 2026 · NCT07405164Familial Investigations of Childhood Cancer Predisposition
- St. Jude Children's Research Hospital, Memphis
RecruitingObservational study
All ages · All sexes · Updated Jun 17, 2026 · NCT03050268From ClinicalTrials.gov, data retrieved Oct 5, 2026. Each study sets its own eligibility; the study team decides who can join.